ReviewPLoS neglected tropical diseases2016
Benchmarking the Cost per Person of Mass Treatment for Selected Neglected Tropical Diseases: An Approach Based on Literature Review and Meta-regression with Web-Based Software Application.
Review in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Economic evaluations of human schistosomiasis interventions: a systematic review and identification of associated research needs.Wellcome open research · 2020Pooled it
- Economic evaluations of onchocerciasis interventions: a systematic review and research needs.Tropical medicine & international health : TM & IH · 2019Pooled it
- Economic Evaluations of Mass Drug Administration: The Importance of Economies of Scale and Scope.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Pooled it
- Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs.Parasites & vectors · 2018Pooled it
- Costs, Coverage, and Acceptability of Azithromycin Mass Administration to Children 1-11 Versus 1-59 Months Old to Reduce Mortality: A Cluster-Randomized Trial in Niger.The American journal of tropical medicine and hygiene · 2025Trial
- A comparison of the diagnostic capability of Kato-Katz and real-time PCR for the assessment of treatment efficacy of ivermectin and albendazole combination against T. trichiura infections.PLoS neglected tropical diseases · 2024Trial
- Trial
- Cost analysis of implementing community-based mass drug administration for schistosomiasis control among adult individuals using community drug distributors in Ukerewe district council, North-Western Tanzania.PLoS neglected tropical diseases · 2026Article
- Cost-effectiveness of soil-transmitted helminthiasis intervention programmes: A scoping review.PLoS neglected tropical diseases · 2026Article
- Micro-costing for national-scale azithromycin mass drug administration to improve child survival in Niger.PLOS global public health · 2026Article
- Reclaiming Rural Medicine: Mass Drug Administration, Community Sovereignty, and Institutional Memory.Cureus · 2025Article
- The changing neglected tropical disease landscape in Africa: implications for policy, practice, and strengthening health systems.Health affairs scholar · 2025Article
- Schistosomiasis and Intestinal Helminthiases in a Remote Area of Central Madagascar.Journal of tropical medicine · 2025Article
- Corneal pannus, Herbert's pits and conjunctival inflammation in older children in Papua New Guinea.Ophthalmic epidemiology · 2024Article
- Cost of implementing a doxycycline test-and-treat strategy for onchocerciasis elimination among settled and semi-nomadic groups in Cameroon.PLoS neglected tropical diseases · 2023Article
- Reach and uptake of mass drug administration for worm infections through health facility-, school-, and community-based approaches in two districts of Zambia: a call for scale-up.Epidemiology and infection · 2023Article
- What are economic costs and when should they be used in health economic studies?Cost effectiveness and resource allocation : C/E · 2023Review
- Global prevalence of 4 neglected foodborne trematodes targeted for control by WHO: A scoping review to highlight the gaps.PLoS neglected tropical diseases · 2023Article
- Comparison of door-to-door and fixed-point delivery of azithromycin distribution for child survival in Niger: A cluster-randomized trial.PLOS global public health · 2023Article
- Exploring the Funding Challenges Faced by Small NGOs: Perspectives from an Organization with Practical Experience of Working in Rural Malawi.Research and reports in tropical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
Abstract
backgroundAdvocacy around mass treatment for the elimination of selected Neglected Tropical Diseases (NTDs) has typically put the cost per person treated at less than US$ 0.50. Whilst useful for advocacy, the focus on a single number misrepresents the complexity of delivering "free" donated medicines to about a billion people across the world. We perform a literature review and meta-regression of the cost per person per round of mass treatment against NTDs. We develop a web-based software application (https://healthy.shinyapps.io/benchmark/) to calculate setting-specific unit costs against which programme budgets and expenditures or results-based pay-outs can be benchmarked.
methodsWe reviewed costing studies of mass treatment for the control, elimination or eradication of lymphatic filariasis, schistosomiasis, soil-transmitted helminthiasis, onchocerciasis, trachoma and yaws. These are the main 6 NTDs for which mass treatment is recommended. We extracted financial and economic unit costs, adjusted to a standard definition and base year. We regressed unit costs on the number of people treated and other explanatory variables. Regression results were used to "predict" country-specific unit cost benchmarks.
resultsWe reviewed 56 costing studies and included in the meta-regression 34 studies from 23 countries and 91 sites. Unit costs were found to be very sensitive to economies of scale, and the decision of whether or not to use local volunteers. Financial unit costs are expected to be less than 2015 US$ 0.50 in most countries for programmes that treat 100 thousand people or more. However, for smaller programmes, including those in the "last mile", or those that cannot rely on local volunteers, both economic and financial unit costs are expected to be higher. DISCUSSION: The available evidence confirms that mass treatment offers a low cost public health intervention on the path towards universal health coverage. However, more costing studies focussed on elimination are needed. Unit cost benchmarks can help in monitoring value for money in programme plans, budgets and accounts, or in setting a reasonable pay-out for results-based financing mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.